REPEATING LATE-PHASE PSEUDO-PROGRESSION IN A PATIENT WITH NON-SMALL CELL LUNG CANCER TREATED WITH LONG-TERM NIVOLUMAB MONOTHERAPY; A CASE REPORT

Repeating late-phase pseudo-progression in a patient with non-small cell lung cancer treated with long-term nivolumab monotherapy; a case report

BackgroundImmune check point inhibitors (ICIs) are standard treatment for patients with non-small cell lung cancer (NSCLC).Nearly a A/C Delete decade has passed since nivolumab was approved by the FDA for NSCLC patients.However, long-term outcomes and clinical features remain unclear for individual cases.Pseudo-progression is a well-known paradoxic

read more